Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PDE4B | Q07343 | 4/20 | 0.45 |
| ▸ | PDE4D | Q08499 | 1/20 | 0.42 |
| ▸ | F10 | P00742 | 2/20 | 0.41 |
| ▸ | F2 | P00734 | 1/20 | 0.41 |
| ▸ | ATF4 | P18848 | 1/20 | 0.41 |
| ▸ | KHK | P50053 | 1/20 | 0.38 |
| ▸ | CHRNA3 | P32297 | 1/20 | 0.37 |
| ▸ | HPGD | P15428 | 1/20 | 0.37 |
| ▸ | MEN1 | O00255 | 1/20 | 0.37 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.37 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.37 |
| ▸ | PDE4A | P27815 | 1/20 | 0.37 |
| ▸ | PDE4C | Q08493 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL22614261 | 1.00 | PDE4B (0.45) | PDE4BPDE4DF10F2ATF4 | |
| SCHEMBL22616356 | 0.94 | PDE4B (0.41) | PDE4BPDE4DF10F2ATF4 | |
| SCHEMBL22616354 | 0.94 | PDE4B (0.41) | PDE4BPDE4DF10F2ATF4 | |
| SCHEMBL28720062 | 0.84 | ALDH1A1 (0.47) | F10F2MEN1ALDH1A1KMT2A | |
| SCHEMBL28720061 | 0.84 | ALDH1A1 (0.47) | F10F2MEN1ALDH1A1KMT2A | |
| SCHEMBL22612457 | 0.78 | ATF4 (0.63) | ATF4 | |
| SCHEMBL22612456 | 0.78 | ATF4 (0.63) | ATF4 | |
| SCHEMBL22614034 | 0.78 | ATF4 (0.42) | PDE4BPDE4DATF4ALDH1A1 | |
| SCHEMBL22614031 | 0.78 | ATF4 (0.42) | PDE4BPDE4DATF4ALDH1A1 | |
| SCHEMBL29159601 | 0.78 | ATF4 (0.42) | PDE4BPDE4DATF4ALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20200347043-A1 | MODULATORS OF THE INTEGRATED STRESS PATHWAY | ABBVIE INC. | 2020-11-05 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20200347043-A1 | MODULATORS OF THE INTEGRATED STRESS PATHWAY | ATF4, ATF1, DDIT3 | PDE4B 2920/4885PDE4D 3734/4885F10 4761/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.